Clozapine prescribing in a Canadian outpatient population

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Alessi Severini, Silvia ^a   Le Dorze, Josee Anne ^a   Nguyen, David ^a   Honcharik, Patricia ^a,b   Eleff, Michael ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGED; ARTICLE; CANADA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; URBAN POPULATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CANADA; CLOZAPINE; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84892734427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083539     Document Type: Article

References (16)

1. Essali A, A-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia (Review). Cochrane Database Syst Rev 1:1-219
2. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F et al. (2010) Clozapine versus other atypical antipsychotics for schizophrenia (Review). Cochrane Database Syst Rev 12: 1-205
3. Meltzer HY, Alphs L, Green AI, Anand R, Bertoli A et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention trial (InterSePT). Arch Gen Psychiatry 60(1): 81-91. PubMed: 12511175.
4. Werneck AP, Hallak JC, Nakano E, Elkis H (2011) Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res 188(3): 315-319. doi: 10.1016/j.psychres.2011.04.004. PubMed: 21596442.
5. Ciudad A, Haro JM, Alonso J, Bousoño M, Suárez D et al. (2008) The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry 1: 1-7. PubMed: 18023154.
6. Taylor M, Shajahan P, Lawrie SM (2008) Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2: 240-245. PubMed: 18363452.
7. Clinical practice guidelines (2005) Treatment of schizophrenia. Can J Psychiatry 13 Suppl 1:7S-57S
8. National Institute of Health and Clinical Excellence (2009). Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care Volumes CG82. March. Available: guidance.nice.org.uk. Accessed April 26, 2013
9. Buchanan RW, Keyenbuhl J, Kelly DL, Noel JM, Boggs DL et al. (2010) The schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophr Bull 36: 94-103. doi:10.1093/schbul/sbp130. PubMed: 19955388.
10. Mcilwain ME, Harrison J, Wheeler AJ, Russell BR (2011) Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 7: 135-149. PubMed: 21552316.
11. Health Canada Clozapine official product monograph. Available: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=11422&lang=eng. Accessed April 26 2013
12. Taylor DM, Young C, Paton C (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 1: 30-34. PubMed: 12590620.
13. Wheeler AJ (2008) Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 6: 852-860. PubMed: 18477732.
14. Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J (2010) Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) Guidance in the real world. Clin Schizophr Relat Psychoses 4: 49-55. doi:10.3371/CSRP.4.1.4. PubMed: 20643629.
15. Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22: 165-182. doi: 10.1016/S0924-977X(12)70232-8. PubMed: 21906915.
16. Barnes TR, the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association of Psychopharmacology. J Psychopharmacol 25(5): 567-620. doi:10.1177/ 0269881110391123. PubMed: 21292923.